martes, 10 de junio de 2014

National Guideline Clearinghouse | American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti–TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.

full-text ►

National Guideline Clearinghouse | American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti–TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.



American Gastroenterological Association Institute

National Guideline Clearinghouse (NGC)

Guideline Title
American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti–TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.
Bibliographic Source(s)
Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT, AGA Institute Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-a biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013 Dec;145(6):1459-63. [2 references] PubMed External Web Site Policy
Guideline Status
This is the current release of the guideline.


 2013 Dec;145(6):1459-63. doi: 10.1053/j.gastro.2013.10.047.

American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.

KEYWORDS:

AGA; American Gastroenterological Association Institute; CD; Crohn's disease; Development and Evaluation; GRADE; Grading of Recommendations Assessment; PICO; TNF; and outcome; comparator; intervention; population; tumor necrosis factor

PMID:
 
24267474
 
[PubMed - indexed for MEDLINE]

No hay comentarios:

Publicar un comentario